Comparative Pharmacology
Head-to-head clinical analysis: JASCAYD versus SPRYCEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JASCAYD versus SPRYCEL.
JASCAYD vs SPRYCEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
JASCAYD (tasquinimod) is a selective allosteric inhibitor of S100A9, which binds to toll-like receptor 4 (TLR4) and receptor for advanced glycation end-products (RAGE). It modulates the tumor microenvironment by inhibiting myeloid-derived suppressor cell (MDSC) recruitment and function, reducing angiogenesis, and enhancing anti-tumor immune responses.
Dasatinib is a dual tyrosine kinase inhibitor targeting BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. It binds to the ATP-binding site of BCR-ABL and inhibits proliferation and induces apoptosis in Philadelphia chromosome-positive (Ph+) leukemic cells.
Adults: 300 mg orally twice daily with food.
100 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours; clinically relevant for once-daily dosing.
Terminal elimination half-life is approximately 3–4 hours for dasatinib, with a longer half-life of 8–10 hours for its active metabolite; clinical context: supports twice-daily dosing.
Primarily renal excretion (80%) as unchanged drug; 20% fecal via biliary elimination.
Primarily fecal (85%) as unchanged drug and metabolites; renal excretion accounts for <10% of the dose.
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor